(Q40786738)

23 September 2017

title

Pilot study of recombinant human interleukin 2 for chronic type B hepatitis (English)

1 reference

23 September 2017

Kakumu S

1

1 reference

23 September 2017

Fuji A

2

1 reference

23 September 2017

Yoshioka K

3

1 reference

23 September 2017

Tahara H

4

1 reference

23 September 2017

Ohtani Y

5

1 reference

23 September 2017

Hirofuji H

6

1 reference

23 September 2017

Murase K

7

1 reference

23 September 2017

Aoi T

8

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 May 1988

1 reference

23 September 2017

1 reference

23 September 2017

volume

8

1 reference

23 September 2017

issue

3

1 reference

23 September 2017

page(s)

487-492

1 reference

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

Antiviral Treatment of Chronic Hepatitis B Virus Infection. I. Changes in Viral Markers with Interferon Combined with Adenine Arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

Spontaneous disappearance of viral replication and liver cell inflammation in HBsAg-positive chronic active hepatitis: results of a placebo vs. interferon trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

Cellular immunity and hepatitis-associated, Australia antigen liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Interleukin 2: a class of T cell growth factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Interleukin-2 augments natural killer cell activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Comparison of the biological properties of purified natural and recombinant human interleukin-2.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Treatment of chronic hepatitis due to hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Interferon in viral hepatitis: role in pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Interferon-gamma production by peripheral blood mononuclear cells of patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080309

7 January 2021

Identifiers

DOI

10.1002/HEP.1840080309

1 reference

23 September 2017

1 reference